{"date":"2025-10-15","count":7,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4745-2025-10-15-2211-1nk1cxv","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-10-15","time":"22:11:27","subject":"公告本公司114年9月份自結應收帳款餘額及回收情形","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-10-15 22:11，「公告本公司114年9月份自結應收帳款餘額及回收情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6885-2025-10-15-1906-1npqjv4","company_id":"6885","company":"全福生技","market":"上市","industry":"生技醫療","date":"2025-10-15","time":"19:06:24","subject":"公告本公司開發中新藥BRM421治療乾眼症第II期劑量探索、安全性與療效性之人體臨床試驗設計重大變更獲衛生福利部核准，將依變更後之臨床設計進行試驗","clause":"第10款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：全福生技（6885），2025-10-15 19:06，「公告本公司開發中新藥BRM421治療乾眼症第II期劑量探索、安全性與療效性之人體臨床試驗設計重大變更獲衛生福利部核准，將」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6499-2025-10-15-1706-zk5u4s","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2025-10-15","time":"17:06:08","subject":"公告本公司114年現金增資認股基準日相關事宜(補充現金增資發行價格、代收及存儲銀行)","clause":"第11款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：益安（6499），2025-10-15 17:06，「公告本公司114年現金增資認股基準日相關事宜(補充現金增資發行價格、代收及存儲銀行)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6659-2025-10-15-1451-ri1roe","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2025-10-15","time":"14:51:33","subject":"公告本公司發放現金股利之配息基準日。","clause":"第9款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2025-10-15 14:51，「公告本公司發放現金股利之配息基準日。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3205-2025-10-15-1355-mj2exn","company_id":"3205","company":"佰研","market":"上櫃","industry":"生技醫療","date":"2025-10-15","time":"13:55:44","subject":"本公司依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第四款規定公告背書保證事項。","clause":"第22款","fact_date":"2025-09-08","cite_as":"公開資訊觀測站重大訊息：佰研（3205），2025-10-15 13:55，「本公司依公開發行公司資金貸與及背書保證處理準則第二十五條第一項第四款規定公告背書保證事項。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-10-15-1344-q203yi","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-10-15","time":"13:44:12","subject":"公告本公司重要營運主管異動案","clause":"第8款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-10-15 13:44，「公告本公司重要營運主管異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-10-15-1343-19ayyd1","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-10-15","time":"13:43:50","subject":"生華科新藥CX-5461獲選美國NCI-NExT計畫的第三項臨床試驗，聯合免疫檢查點抑制劑Cemiplimab治療難治性微衛星穩定型結直腸癌第1/2期人體試驗已獲美國FDA核准執行。","clause":"第53款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-10-15 13:43，「生華科新藥CX-5461獲選美國NCI-NExT計畫的第三項臨床試驗，聯合免疫檢查點抑制劑Cemiplimab治療難治性」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}